GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (STU:1S70) » Definitions » Additional Paid-In Capital

Cartesian Therapeutics (STU:1S70) Additional Paid-In Capital : €514.53 Mil(As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cartesian Therapeutics Additional Paid-In Capital?


Cartesian Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€470.30 Mil) to Dec. 2023 (€164.19 Mil) but then increased from Dec. 2023 (€164.19 Mil) to Mar. 2024 (€514.53 Mil).

Cartesian Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€404.79 Mil) to Dec. 2022 (€465.68 Mil) but then declined from Dec. 2022 (€465.68 Mil) to Dec. 2023 (€164.19 Mil).


Cartesian Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Cartesian Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Additional Paid-In Capital Chart

Cartesian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 313.80 321.55 404.79 465.68 164.19

Cartesian Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 463.02 459.67 470.30 164.19 514.53

Cartesian Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cartesian Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics (STU:1S70) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Cartesian Therapeutics (STU:1S70) Headlines

No Headlines